EGFR and non-small cell lung carcinoma: In recent years, a number of molecular targeted therapies, such as epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors and an inhibitor of echinoderm microtubule-associated protein-like 4-anaplastic lymphoma receptor tyrosine kinase (EML4-ALK), have been developed for the treatment of non-small cell lung cancer.